Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT-Reference-Cited by-同舟云学术

Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT

Published:2023-11-08 Issue:1 Volume:103 Page:307-320
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Nakagawa Noriharu,Ishiyama Ken^ORCID,Usuki Kensuke,Takada Satoru,Tomikawa Tatsuki,Handa Hiroshi,Katsuoka Yuna,Hirano Daiki,Sezaki Nobuo,Sumi Masahiko,Fujisawa Shin,Taniguchi Yasuhiro,Mugitani Atsuko,Yoshimura Takuro,Ohtsuka Eiichi,Takase Ken,Suehiro Youko,Ota Shuichi,Kajiguchi Tomohiro,Maeda Tomoya,Yamamoto Masahide,Ohtake Shigeki,Katsumi Akira,Kiyoi Hitoshi,Matsumura Itaru,Miyazaki Yasushi

Funder

Japan Adult Leukemia Study Group

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-023-05527-5.pdf

Reference29 articles.

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51(2):189–199

2. Cazzola M, Malcovati L (2005) Myelodysplastic syndromes–coping with ineffective hematopoiesis. N Engl J Med 352(6):536–538. https://doi.org/10.1056/NEJMp048266

3. Robin M, Porcher R, Adès L, Raffoux E, Michallet M, François S, Cahn JY, Delmer A, Wattel E, Vigouroux S, Bay JO, Cornillon J, Huynh A, Nguyen S, Rubio MT, Vincent L, Maillard N, Charbonnier A, de Latour RP, Reman O, Dombret H, Fenaux P, Socié G (2015) HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM. Leukemia 29(7):1496–1501. https://doi.org/10.1038/leu.2015.37

4. Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk J, Westervelt P, Vasu S, Patnaik M, Kamble R, Forman SJ, Sekeres MA, Appelbaum F, Mendizabal A, Logan B, Horowitz M, Cutler C (2021) Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50–75 years of age with advanced myelodysplastic syndrome. J Clin Oncol: Off J Am Soc Clin Oncol 39(30):3328–3339. https://doi.org/10.1200/jco.20.03380

5. Kröger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D, Stadler M, Kobbe G, Wulf G, Bug G, Schäfer-Eckart K, Scheid C, Nolte F, Krönke J, Stelljes M, Beelen D, Heinzelmann M, Haase D, Buchner H, Bleckert G, Giagounidis A, Platzbecker U (2021) Comparison between 5-Azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study). J Clin Oncol: Off J Am Soc Clin Oncol 39(30):3318–3327. https://doi.org/10.1200/jco.20.02724